Table 3d. Therapeutic Management of Hospitalized Pediatric Patients With MIS-C
Last Updated: February 24, 2022
|Patient Condition||Panel’s Recommendations|
|MIS-C||Initial treatment for MIS-C includes both immunomodulatory and antithrombotic therapy.|
Initial Immunomodulatory Therapy:
|Rating of Recommendations: A = Strong; B = Moderate; C = Weak|
Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion
a Duration of therapy may vary. See duration in table and text below.
b In certain patients with severe illness, intensification therapy may include dual therapy with higher-dose glucocorticoids and infliximab or anakinra. Anakinra and infliximab should not be given in combination..
c Infliximab should not be used in patients with macrophage activation syndrome.
Key: CAA = coronary artery aneurysm; IBW = ideal body weight; IV = intravenous; IVIG = intravenous immunoglobulin; LV = left ventricular; MIS-C = multisystem inflammatory syndrome in children; PO = oral; SUBQ = subcutaneously